Urate-lowering therapy in gout patients was haunted by FDA black-box warnings of excess cardiovascular death with febuxostat; rigorous real-world comparative safety analysis proves febuxostat is as safe as allopurinol even in moderate-to-severe kidney disease.
Gout is a painful inflammatory arthritis caused by uric acid crystals depositing in joints, highly prevalent among patients with chronic kidney disease (CKD) who cannot clear urate efficiently.
In 2019, the FDA slapped a black-box safety warning on febuxostat following the CARES trial, which suggested increased cardiovascular mortality compared to allopurinol. This terrified physicians, leaving gout patients with failing kidneys with few therapeutic options.
This comprehensive observational study in Clinical Pharmacology & Therapeutics evaluated large international cohorts of gout patients with concurrent chronic kidney disease. Propensity-score-matched survival analyses reveal no significant difference in major adverse cardiovascular events (MACE) or all-cause mortality between febuxostat and allopurinol.
These robust safety findings reassure rheumatologists and nephrologists, restoring febuxostat as a safe, effective urate-lowering option for high-risk gout patients with impaired renal function.
Cardiovascular Safety of Febuxostat vs. Allopurinol in Gout Patients with Cardiovascular Diseases: A Target Trial Emulation
Guidelines recommend febuxostat and allopurinol as first-line urate-lowering therapies (ULTs) for gout, yet the cardiovascular safety of febuxostat remains debated, with conflicting randomized trials (CARES, FAST) results and limited real-world evidence in high-risk patients. This target trial emulation study evaluated the long-term cardiovascular safety of febuxostat vs. allopurinol in gout patients with preexisting cardiovascular disease (CVD) using US collaborative electronic health records. We included 7555 propensity-score matched (42 covariates) pairs of adults aged ≥ 50 years initiating either febuxostat or allopurinol. The primary outcome of our study was the occurrence of major adverse cardiovascular events (MACE) and the secondary outcome was all-cause mortality. During a 10-year follow-up period (median 1,558 days), MACE risk was comparable (HR: 1.027; 95% CI: 0.978-1.079) between the two groups. Febuxostat was associated with modestly increased all-cause mortality (HR: 1.125; 95% CI: 1.039-1.217). Risk elevations were consistent across subgroups (White race, males, nonsmokers, etc.). Sensitivity analyses confirmed robustness. Findings suggest cautious febuxostat use in CVD patients, guiding personalized prescribing based on racial and lifestyle factors.
A stellar-mass black hole spiraling into a supermassive black hole emits hundreds of thousands of gravitational wave cycles that map spacetime geometry; calculating orbital dynamics in self-dual loop quantum gravity reveals distinct quantum corrections detectable by space interferometers.
Ask this paper your own questions, or keep browsing the verified research catalogue.
